Introduction {#sec1-1}
============

Aspects of cancer pain, such as increasing intensity and duration, have been linked to diminished quality of life, poor functioning and psychological distress, regardless of differences in measurement and type of patients.^[@ref1]^ Pain acceptance could help cancer patients adapt to pain, since it has proven valuable in determining physical and emotional adjustment to chronic non-malignant pain.vPain acceptance refers to the continuation of activities despite experiencing pain, as well as the willingness to accept the presence of pain in order to discontinue futile attempts to control it and live a satisfying life.^[@ref4]^ Acceptance has been associated with improved emotional, physical and social functioning in chronic pain sufferers.^[@ref5],[@ref6]^ However, several studies have found no significant association between acceptance and pain intensity or physical functioning.^[@ref7]^

Similarities in pain, activity and emotional distress between cancer and chronic non-cancer patients provide ground for exploration of the impact of the psychological therapeutic construct of acceptance within the context of cancer pain. To our knowledge, only one quantitative study has investigated pain acceptance in a cancer population. Gauthier *et al.*^[@ref10]^ reported an association between pain acceptance and psychological well-being in patients with advanced cancer, but no association with pain or physical function. This finding has important implications, especially given that cancer patients frequently experience co-morbid pain and depression,^[@ref2]^ two factors that react to one another and share common biological pathways.^[@ref11]^ The neurotransmitter imbalance occurring in depression is associated with greater sensitivity to pain and changes in pain perception.^[@ref11],[@ref12]^ However, the direction of causality between pain and depression remains unspecified,^[@ref13]^ and it is possible that activity restriction may mediate the pain-depression relationship.^[@ref14]^ Additionally, evidence of the association between cancer pain and anxiety is limited; it is unclear whether anxiety exists due to variables occurring mainly in outpatient settings, such as waiting for procedures or test results.^[@ref17],[@ref18]^ Studies have reported that patients' functional status and life disruption are critical in predicting abnormal anxiety levels.^[@ref17],[@ref19]^

In light of these findings, we wished to further explore the effect of acceptance on physical and psychological well-being. Our aim was to determine whether pain acceptance predicts pain, pain-related functional interference, anxiety and depression in cancer outpatients.

Materials and Methods {#sec1-2}
=====================

Ethics approval was obtained from the University of Surrey Faculty of Arts and Human Sciences Ethics Committee and the Cyprus Bioethics Committee. Participants were consecutive outpatients at the day care center of the Bank of Cyprus Oncology Centre (BOCOC) in Cyprus, attending for chemotherapy and maintenance drug administration or doctor appointments. Eligible participants were over 18 years of age, with any type of cancer and any level of cancer pain.

We recruited a sample of 145 consecutive cancer outpatients at the day care center in August 2010, of which 4 (3%) were excluded due to incomplete responses, and 35 (24%) were excluded because they experienced no cancer-related pain. Outpatients gave their informed consent, completed the questionnaires and returned them to the researcher (EP). After completion of the questionnaires, the researcher debriefed participants about the purpose of the study and the assessment measures used.

All assessment measures and forms were translated from English to Greek, and verified for grammar and comprehension. An independent translator then translated the forms and questionnaires back from Greek to English. There were virtually no differences between the original versions and the back translation. Participants were given either English or Greek questionnaires depending on the language they felt most comfortable with.

Measures {#sec2-1}
--------

### Demographic and medical factors {#sec3-1}

Demographic variables recorded for each participant included age, sex, family situation, educational level, work status and nationality. Reported medical factors included disease and treatment information such as primary cancer site, presence of metastasis, illness duration, pain location, cancer treatment and pain treatment. The level of pain treatment was coded according to the World Health Organization (WHO) analgesic ladder.^[@ref20]^ Therefore, pain treatment was coded as none, Paracetamol/NSAIDs, weak opioids and strong opioids. We also dichotomised pain treatment as treatment received or not.

### Pain assessment {#sec3-2}

The Brief Pain Inventory (BPI)^[@ref21]^ was used to assess two main dimensions; pain severity (sensory dimension) and pain interference with several aspects of daily functioning (reactive dimension). The short-form version (BPI-SF) used in this study assesses worst and least pain in the past 24 hours, average pain, and pain experienced at the time of questionnaire completion on an 11-point rating scale (0-10) with the anchors *no pain* and *pain as bad as you can imagine.* In addition, pain interference with general activity, mood, walking ability, normal work, relations with others, sleep and life enjoyment is rated on an 11-point rating scale with the anchors *does not interfere* and *completely interferes.* Scores of the 4 items measuring worst, least, average and current pain are added-up and divided by the number of items in order to calculate total pain severity. The scores of the 7 interference items are also added up and divided by the number of items to calculate total pain interference. Total pain severity and total pain interference scores range from 0-10. Cronbach's alpha for the Severity and Interference scales was 0.88 and 0.93 respectively.

### Psychological distress {#sec3-3}

Anxiety and depression levels were measured with the Hospital Anxiety and Depression scale, a screening tool with the purpose of identifying co-morbid anxiety and depression in populations found in medical settings.^[@ref22]^ The HAD scale focuses on non-somatic symptoms of anxiety and depression, such as autonomic anxiety and unhedonia. The scale consists of 14 items; 7 items for the anxiety subscale and 7 for the depression subscale. Each item is scored on a 4-point scale ranging from 0-3, yielding a total score of 0-21 for each subscale. Cronbach's alpha for the Anxiety and Depression scales was 0.85 and 0.79 respectively.

### Acceptance {#sec3-4}

The Chronic Pain Acceptance Questionnaire (CPAQ)^[@ref23]^ measures the degree to which the patient accepts pain as a part of daily life and carries on with general activities as normal. The revised 20-item version was used in the present study.^[@ref24]^ The CPAQ questionnaire consists of two subscales; Activity Engagement and Pain Willingness. Activity Engagement refers to the continuation of activities as normal even if experiencing pain, whereas Pain Willingness refers to the individual's willingness, as opposed to reluctance, to experience pain without futile attempts to control it. Each item of the questionnaire is rated on a 7-point rating scale ranging from 0-6, depending on the extent to which each statement applies to the participant (*e.g.* 0=never true and 6=always true). Scores for Activity Engagement range from 0 to 66 and for Pain Willingness from 0 to 54. Cronbach's alpha for the Activity Engagement and Pain Willingness subscales was 0.83 and 0.84 respectively.

Statistical analysis {#sec2-2}
--------------------

Data were screened for accuracy, missing values and normal distribution. They were not normally distributed, therefore we carried out non parametric univariate analyses.

Demographic, disease and treatment characteristics were collected to describe the sample. Univariate analyses such as Mann-Whitney U, Kruskall-Wallis H and Spearman's correlations were carried out where appropriate to assess the relationship between sample characteristics and assessment measures. Patient characteristics and outcome variables that were significantly associated with other patient outcomes and the acceptance subscales at 0.05 in univariate analyses were included in the multiple regression model. Multicollinearity was tested by examining values of Tolerance and Variance Inflation Factor (VIF). Data were analyzed using SPSS (Statistical Package for the Social Sciences; Chicago, IL, USA) v.21.0.1.

Results {#sec1-3}
=======

Patient characteristics {#sec2-3}
-----------------------

Of the 116 participants included in the study ([Table 1](#table001){ref-type="table"}) the majority were female (76.7%), married (83.6%) and of Greek Cypriot nationality (89.7%). Ages ranged from 18 to 79 years (M=56.23, SD=12.26).

Participants' medical characteristics revealed that breast cancer was the most common diagnosis (52.6%) and that 43 (37.1%) patients had metastatic disease. Cancer duration ranged from 1 month to 22 years (M=39.21 months, SD=52.91). The most frequently reported pain locations were the chest (31.9%), abdomen (29.3%) and back (21.6%). Most participants were receiving cancer treatment (81.9%) and Paracetamol/Non-steroidal anti-inflammatory drugs (38.8%), while 52.5% of patients reported receiving no pain medication despite indicating that they experienced pain. Pain treatment was classified according to guidelines for cancer pain relief by the World Health Organization.^[@ref20]^

Univariate analyses {#sec2-4}
-------------------

### Acceptance {#sec3-5}

Univariate non parametric analyses were carried out in order to detect any significant associations between patient characteristics and acceptance subscales. Participants who were working had significantly higher activity engagement scores (P=0.027) compared to those not working. Patients' primary cancer site influenced their activity engagement scores (P=0.009). Gynecological/genitourinary cancers had the lowest activity engagement scores (29.56±15.45). Pain in the abdomen was associated with lower activity engagement (P=0.044). Patients receiving pain treatment had significantly lower activity engagement (P=0.005). Pain willingness was not associated with patient characteristics.

### Patient outcomes {#sec3-6}

Further univariate analyses identified associations between patient characteristics and outcome measures.

A higher education level was associated with lower pain (r=-0.228, P=0.014), anxiety (r=-0.287, P=0.002) and depression (R=-0.189, P=0.042) scores. Participants who were working had significantly lower anxiety (P=0.044) and depression scores (P=0.019), compared to those not working. Patients' primary cancer site influenced their pain interference (P=0.008), depression (P=0.004) and activity engagement scores (P=0.009). Gynecological/genitourinary cancers had the highest mean pain interference scores (5.82±2.68), while lung cancer patients had the highest depression scores (12.00± 3.94). Back pain was associated with higher pain severity (P=0.45), as was pain in the abdomen (P=0.031). Patients with 2-4 pain sites had higher pain severity (P=0.41) and pain interference scores (P=0.42). Patients receiving pain treatment had significantly higher scores of pain severity (P=0.014), pain interference (P=0.013), anxiety (P\<0.001), and depression (P\<0.001).

Bivariate associations between pain acceptance and physical and psychological outcomes {#sec2-5}
--------------------------------------------------------------------------------------

Spearman's correlations ([Table 2](#table002){ref-type="table"}) revealed that activity engagement was significantly correlated with pain severity, pain interference, anxiety and depression. Pain willingness was weakly correlated with pain severity and pain interference.

### Linear multiple regression: role of acceptance subscales in predicting outcomes {#sec3-7}

Multiple regression was used to determine the extent to which Activity Engagement and Pain Willingness predict physical and psychological outcomes. Patient demographic and medical characteristics significant at P\<0.05 were included in the model when associated with the outcome variable, or both the predictor and outcome. Neither acceptance subscale predicted pain severity.

Activity engagement and pain willingness, together with gynecological/genitourinary cancer, pain severity and depression accounted for 59% of the variance in pain interference with function, \[F(8,107)=18.94, P\<0.001\] ([Table 3](#table003){ref-type="table"}).

Activity engagement, in addition to education, pain treatment and interference, accounted for 33% of the variance in anxiety \[F(6,109)=8.89, P\<0.001\] ([Table 4](#table004){ref-type="table"}).

Activity engagement, together with lung cancer site, pain treatment and pain interference accounted for 56% of the variance in depression scores \[F(7,108)=19.71, P\<0.001\] ([Table 5](#table005){ref-type="table"}).

Discussion {#sec1-4}
==========

The aim of the present study was to investigate the role of pain acceptance in physical and functional outcomes (pain interference with daily life) and psychological (anxiety and depression) outcomes in a sample of outpatients with cancer pain. The activity engagement subscale of the acceptance measure predicted pain interference, anxiety, and depression. The pain willingness subscale predicted only pain interference and not the psychological outcomes of anxiety and depression. Neither acceptance subscale played a role in predicting pain severity. Our findings replicate and extend those of the only previous study we are aware of investigating the role of acceptance in a cancer population.^[@ref10]^ We replicate the finding that greater activity engagement predicts better psychological outcomes. We extend this previous research with our finding that both pain willingness and activity engagement seem to play a role in the extent to which pain interferes with everyday functioning. It should be noted that, outside of the cancer literature, most acceptance studies have found associations between physical and psychosocial functioning with both acceptance subscales and with overall acceptance.^[@ref6],[@ref8],[@ref9],[@ref25]^

Thus, our findings support the growing consensus that acceptance is associated with improved emotional, physical, and social functioning in the wider pain literature.^[@ref5],[@ref9]^ This is of substantial interest given that acceptance appears to be a modifiable construct that is amenable to intervention. A recent systematic review and meta-analysis of acceptance-based interventions for the treatment of chronic pain found that acceptance-based interventions across different chronic pain populations improve both pain intensity and physical well-being, as well as depression, anxiety, and quality of life.^[@ref26]^ The authors did not break down the analysis by acceptance subscales, but our findings suggest that focusing interventions on continuing activities as normal despite pain will be most useful for improving both physical and psychological outcomes, at least in cancer patients. Our findings also suggest that interventions which focus on being willing to experience pain without futile attempts to control it may also be useful for improving the extent to which pain interferes with everyday living, but possibly not for improving psychological well-being. Perhaps the willingness to experience pain is unrealistic in cancer patients, especially since cancer pain could signify tumor growth and disease progression.^[@ref27]^ Most research concerning acceptance applies to chronic pain populations, and although the same physiological mechanisms may be involved in both cancer pain and non-malignant pain,^[@ref28]^ it cannot be ignored that tumor-related factors or individual response to cancer treatment are likely to affect cancer patients' physical and psychosocial functioning. The fact that the severity of cancer pain was not associated with acceptance measures in multivariate analyses also, perhaps, suggests that acceptance-based interventions may be effective whatever level of cancer pain is being experienced. However, this hypothesis awaits testing.

Activity engagement, but not pain willingness, was also associated with certain patient characteristics in the present study. Participants who were working reported higher activity engagement, as in studies on non-malignant pain.^[@ref4],[@ref6]^ It may be that a willingness to continue as normal with activities helps people with a cancer diagnosis to retain their work. Alternatively, it may be that continuing to work despite the cancer diagnosis leads to improvements in activity engagement. Activity engagement also varied by cancer site and pain site, with gynecological/genitourinary cancers and pain in the abdomen being associated with the lowest activity engagement scores. The reason for these findings is not known and needs to be replicated with a larger study focused primarily upon this research question. Additionally, participants in our study receiving pain treatment had lower activity engagement scores, whereas McCracken and Eccleston^[@ref6]^ reported increased use of medication in patients with lower pain willingness. It is possible that attempts to control pain through medical means may sit uncomfortably alongside the notion of acceptance expressed as continuing engagement with normal activities despite pain. It would be interesting to see whether acceptance-based interventions are differentially effective depending on whether patients are also taking analgesics or not.

This study is not without limitations. The majority of participants were female, with breast cancer, aged 60-69, Greek Cypriot and married, therefore it may be difficult to generalize findings. However, results are mainly consistent with studies in diverse cultural populations despite variability in assessment measures, suggesting that cancer pain and psychological co-morbidity are universal factors. Due to the cross-sectional study design, data were collected at one point in time in the form of self-report measures, engendering the possibility of discrepancy between reported results and actual behavior. Despite this, patients' subjective perception of pain, distress and behavior were of primary research interest. Effects of fatigue, insomnia, apprehension about the diagnosis or medical visit and effects of pharmacological treatments may have possibly occurred at varying degrees during questionnaire completion. It is also difficult to assess psychological health especially when there is confusion between normal sadness due to physical illness and abnormal clinical depression.^[@ref29]^ Depressive symptoms exist in a broad range, which may be complicated to assess while the patient's life is threatened or while they are tired, in pain and receiving cancer treatment.^[@ref30]^ This aspect is controlled by the fact that the Hospital Anxiety and Depression scale rules out somatic symptoms of depression, or in this case somatic symptoms possibly resulting from cancer and its treatment. Results of this study and previous cancer pain studies are similar to chronic pain research findings which verify that non-malignant pain has similar associations with mental health in both inpatient and outpatient settings.^[@ref11],[@ref31],[@ref32]^

Conclusions {#sec1-5}
===========

The present study provides additional evidence for the role of acceptance in adaptation to pain interference with function and psychological distress in cancer outpatients. Prospective studies could include both outpatients and hospitalized patients to detect any significant differences in levels of pain and distress between the two patient categories,^[@ref33]^ and how these are influenced by acceptance. Further prospective confirmation of which components of pain acceptance predict cancer patient outcomes would be a step towards establishing their potential use in acceptance-based and cognitive-behavioral interventions for cancer pain. Special focus could be applied to the potential role of Activity Engagement in mediating pain interference, anxiety, and depression.

We would like to thank staff members at the Bank of Cyprus Oncology Centre who contributed by facilitating this research project. Special thanks to the participants for dedicating their time and effort.

###### 

Sample characteristics (N=116).

                                                                     Mean±SD (frequency)
  ------------------------------------------------------------------ ---------------------
  Age (range: 18-79)                                                 56.23±12.26
  Sex                                                                
     Male                                                            27 (23.3%)
     Female                                                          89 (76.7%)
  Ethnicity                                                          
     Greek/Greek-Cypriot                                             102 (87.9%)
     Other                                                           14 (12.1%)
  Education                                                          
     Primary school                                                  28 (24.1%)
     High school                                                     54 (46.6%)
     College/university                                              34 (29.3%)
  Work status                                                        
     Employed (full/part-time)                                       40 (34.5%)
     Not working (unemployed/homemaker/retired/student)              51 (44.0%)
     Not working due to illness (on sick leave/medical retirement)   25 (21.6%)
  Marital status                                                     
     Married/co-habiting                                             97 (83.6%)
     Single/separated/widowed                                        19 (16.4%)
  Primary cancer site                                                
     Breast                                                          61 (52.6%)
     Gastrointestinal                                                24 (20.7%)
     Lung                                                            9 (7.8%)
     Gynaecologic/genito-urinary                                     11 (9.5%)
     Other                                                           11 (9.5%)
     Cancer duration, months (range: 1-264)                          39.21±52.91
     Metastasis                                                      43 (37.1%)
     No metastasis                                                   73 (62.9%)
     Cancer treatment                                                96 (82.8%)
     No cancer treatment                                             20 (17.2%)
  Cancer treatment                                                   
     Chemotherapy                                                    70 (60.3%)
     Targeted therapy ± chemotherapy                                 21 (18.1%)
     Radiotherapy ± chemotherapy                                     4 (3.4%)
     No cancer treatment                                             21 (18.1%)
  Pain site (multi-response variable)                                
     Head and neck                                                   12 (10.3%)
     Chest                                                           37 (31.9%)
     Back                                                            25 (21.6%
     Abdomen                                                         34 (29.3%)
     Pelvic region                                                   6 (5.2%)
     Upper limbs                                                     12 (10.3%)
     Lower limbs                                                     20 (17.2%)
     Bones                                                           7 (6.0%)
     Unknown                                                         5 (4.3%)
  No. of reported pain sites                                         
     1                                                               76 (65.5%)
     2-4                                                             35 (30.2%)
  Pain treatment (highest WHO class of analgesics reported)          
     None                                                            59 (50.9%)
     Paracetamol/NSAIDs                                              45 (38.8%)
     Weak opioids                                                    2 (1.7%)
     Strong opioids                                                  10 (8.6%)
  Pain treatment                                                     57 (49.1%)
  No pain treatment                                                  59 (50.9%)

###### 

Descriptive statistics and correlation matrix of measures.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                               Mean±SD       BPI - severity                                   BPI - interference                                 HADS-anxiety                                     HADS-depression                                  CPAQ-activity engagement
  ---------------------------- ------------- ------------------------------------------------ -------------------------------------------------- ------------------------------------------------ ------------------------------------------------ --------------------------
  BPI severity                 3.33±1.83                                                                                                                                                                                                           

  BPI interference             3.95±2.51     0.618[\*](#table2-tfn1){ref-type="table-fn"}\                                                                                                                                                         
                                             P\<0.001                                                                                                                                                                                              

  HADS - anxiety               7.61 ±4.48    0.310[\*](#table2-tfn1){ref-type="table-fn"}\    0.424[\*](#table2-tfn1){ref-type="table-fn"}\                                                                                                        
                                             P=0.001                                          P\<0.001                                                                                                                                             

  HADS - depression            6.51±4.18     0.363[\*](#table2-tfn1){ref-type="table-fn"}\    0.546[\*](#table2-tfn1){ref-type="table-fn"}\      0.662[\*](#table2-tfn1){ref-type="table-fn"}\                                                     
                                             P\<0.001                                         P\<0.001                                           P\<0.001                                                                                          

  CPAQ - activity engagement   42.08±13.57   -0.252[\*](#table2-tfn1){ref-type="table-fn"}\   -0.432[\*](#table2-tfn1){ref-type="table-fn"}\     -0.483[\*](#table2-tfn1){ref-type="table-fn"}\   -0.571[\*](#table2-tfn1){ref-type="table-fn"}\   
                                             P=0.006                                          P\<0.001                                           P\<0.001                                         P\<0.001                                         

  CPAQ - pain willingness      18.07±11.22   -0.182\                                          -0.199[\*\*](#table2-tfn2){ref-type="table-fn"}\   -0.018\                                          -0.128\                                          -0.130\
                                             P=0.051                                          P=0.033                                            P=0.850                                          P=0.171                                          P=0.166
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BPI, Brief Pain Inventory; HADS-A, Hospital Anxiety and Depression Scale-Anxiety; HADS-D, Hospital Anxiety and Depression Scale-Depression; CPAQ, Chronic Pain Acceptance Questionnaire.

\*Significant at 0.01 (two-tailed)

\*\*Significant at 0.05 (two-tailed).

###### 

Multiple regression with pain interference as the outcome variable.

  Pain interference Predictors         B       SE     Beta    P                                                95% CI for B
  ------------------------------------ ------- ------ ------- ------------------------------------------------ --------------
  Constant                             2.18    1.04           0.039                                            0.11, 4.25
  Gynecological/genitourinary cancer   1.39    0.56   0.16    0.014[\*](#table3-tfn1){ref-type="table-fn"}     0.28, 2.49
  No. of pain sites (≥2)               0.40    0.24   0.11    0.097                                            -0.07, 0.87
  Pain treatment                       -0.10   0.35   -0.02   0.782                                            -0.79, 0.60
  BPI - severity                       0.55    0.10   0.40    0.00[\*\*](#table3-tfn2){ref-type="table-fn"}    0.36, 0.74
  HADS - anxiety                       0.02    0.05   0.04    0.673                                            -0.08, 0.12
  HADS - depression                    0.16    0.06   0.27    0.007[\*\*](#table3-tfn2){ref-type="table-fn"}   0.04, 0.28
  CPAQ - activity engagement           -0.03   0.02   -0.17   0.033[\*](#table3-tfn1){ref-type="table-fn"}     -0.06, -0.00
  CPAQ - pain willingness              -0.03   0.02   -0.14   0.041[\*](#table3-tfn1){ref-type="table-fn"}     -0.06, -0.00

\*Significant at 0.05

\*\*Significant at 0.01.

###### 

Multiple regression with anxiety as the outcome variable.

  Predictors                   B       SE     Beta    P                                                95% CI for B
  ---------------------------- ------- ------ ------- ------------------------------------------------ --------------
  Constant                     11.75   2.7            0.000                                            6.40, 17.10
  Education                    -1.07   0.52   -0.18   0.042[\*](#table4-tfn1){ref-type="table-fn"}     -2.1, -0.04
  Work status                  -0.14   0.81   -0.01   0.867                                            -1.72, 1.45
  Pain treatment               1.49    0.73   0.17    0.044[\*](#table4-tfn1){ref-type="table-fn"}     0.04, 2.93
  BPI - severity               -0.04   0.25   -0.02   0.882                                            -0.53, 0.45
  BPI - interference           0.44    0.19   0.25    0.023[\*](#table4-tfn1){ref-type="table-fn"}     0.06, 0.82
  CPAQ - activity engagement   -0.1    0.03   -0.30   0.001[\*\*](#table4-tfn2){ref-type="table-fn"}   -0.16, -0.04

\*Significant at 0.05

\*\*Significant at 0.01.

###### 

Multiple regression with depression as the outcome variable.

  Predictors                   B       SE     Beta    P                                              95% CI for B
  ---------------------------- ------- ------ ------- ---------------------------------------------- --------------
  Constant                     7.54    2.10           0.000                                          3.38, 11.71
  Education                    -0.43   0.40   -0.07   0.289                                          -1.21, 0.37
  Work status                  0.51    0.61   0.06    0.409                                          -0.71, 1.73
  Lung cancer                  3.30    1.04   0.21    0.002[\*](#table5-tfn1){ref-type="table-fn"}   1.24, 5.36
  Pain treatment               1.70    0.56   0.20    0.003[\*](#table5-tfn1){ref-type="table-fn"}   0.59, 2.81
  BPI - severity               -0.06   0.19   -0.03   0.760                                          -0.43, 0.32
  BPI - interference           0.57    0.15   0.34    0.000[\*](#table5-tfn1){ref-type="table-fn"}   0.28, 0.86
  CPAQ - activity engagement   -0.10   0.02   -0.32   0.000[\*](#table5-tfn1){ref-type="table-fn"}   -0.14, -0.05

\*Significant at 0.01.
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